Drug Profile
Research programme: Haemophilia A therapeutics - Asklepios BioPharmaceutical
Alternative Names: BNP VIII; BNP-FVIIILatest Information Update: 27 May 2021
Price :
$50
*
At a glance
- Originator Asklepios BioPharmaceutical
- Class
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haemophilia A
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for preclinical development in Haemophilia-A in USA (Parenteral)
- 08 Mar 2012 Preclinical trials in Haemophilia A in USA (Parenteral)